Upregulation of the NKG2D Ligand ULBP2 by JC Polyomavirus Infection Promotes Immune Recognition by Natural Killer Cells.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE
    • Publication Information:
      Publication: Jan. 2011- : Oxford : Oxford University Press
      Original Publication: 1904-2010 : Chicago, IL : University of Chicago Press
    • Subject Terms:
    • Abstract:
      Background: JC polyomavirus (JCPyV) causes progressive multifocal leukoencephalopathy (PML), a potentially fatal complication of severe immune suppression with no effective treatment. Natural killer (NK) cells play critical roles in defense against viral infections; however, NK-cell response to JCPyV infection remains unexplored.
      Methods: NK- and T-cell responses against the JCPyV VP1 were compared using intracellular cytokine staining upon stimulation with peptide pools. A novel flow cytometry-based assay was developed to determine NK-cell killing efficiency of JCPyV-infected astrocyte-derived SVG-A cells. Blocking antibodies were used to evaluate the contribution of NK-cell receptors in immune recognition of JCPyV-infected cells.
      Results: In about 40% of healthy donors, we detected robust CD107a upregulation and IFN-γ production by NK cells, extending beyond T-cell responses. Next, using the NK-cell-mediated killing assay, we showed that coculture of NK cells and JCPyV-infected SVG-A cells leads to a 60% reduction in infection, on average. JCPyV-infected cells had enhanced expression of ULBP2-a ligand for the activating NK-cell receptor NKG2D, and addition of NKG2D blocking antibodies decreased NK-cell degranulation.
      Conclusions: NKG2D-mediated activation of NK cells plays a key role in controlling JCPyV replication and may be a promising immunotherapeutic target to boost NK-cell anti-JCPyV activity.
      Competing Interests: Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
      (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: [email protected].)
    • References:
      AIDS. 2019 Oct 1;33(12):1954-1956. (PMID: 31490218)
      J Neurovirol. 2018 Oct;24(5):652-655. (PMID: 29987583)
      Front Immunol. 2021 Jul 29;12:713158. (PMID: 34394116)
      JAMA Neurol. 2014 Aug;71(8):1030-5. (PMID: 24979548)
      N Engl J Med. 2018 Oct 11;379(15):1443-1451. (PMID: 30304652)
      Front Immunol. 2018 Oct 17;9:2290. (PMID: 30386329)
      World J Gastroenterol. 2016 Jan 28;22(4):1449-60. (PMID: 26819513)
      Proc Natl Acad Sci U S A. 1985 Feb;82(4):1257-61. (PMID: 2983332)
      J Virol. 2011 Jul;85(14):7256-63. (PMID: 21543472)
      FASEB J. 2013 Jun;27(6):2440-50. (PMID: 23395909)
      Front Immunol. 2017 Nov 14;8:1496. (PMID: 29184550)
      J Acquir Immune Defic Syndr. 2019 Oct 1;82(2):220-224. (PMID: 31513076)
      Nat Rev Immunol. 2022 Feb;22(2):112-123. (PMID: 34117484)
      J Virol. 2014 Aug;88(15):8349-54. (PMID: 24829350)
      J Med Virol. 2003 Sep;71(1):115-23. (PMID: 12858417)
      J Immunol. 2010 Sep 1;185(5):2808-18. (PMID: 20679529)
      Nat Rev Neurol. 2021 Jan;17(1):37-51. (PMID: 33219338)
      Int Immunol. 2008 Aug;20(8):981-91. (PMID: 18544572)
      J Immunother Cancer. 2021 Oct;9(10):. (PMID: 34599028)
      Clin Microbiol Rev. 2012 Jul;25(3):471-506. (PMID: 22763635)
      Cell Immunol. 2012 Mar-Apr;276(1-2):122-7. (PMID: 22613008)
      Nature. 2001 Sep 13;413(6852):165-71. (PMID: 11557981)
      Blood Adv. 2020 Jun 9;4(11):2387-2391. (PMID: 32484854)
      N Engl J Med. 1989 Jun 29;320(26):1731-5. (PMID: 2543925)
      Annu Rev Immunol. 2023 Apr 26;41:17-38. (PMID: 36446137)
      Neurology. 2014 Jul 8;83(2):134-41. (PMID: 24907236)
      Lancet Neurol. 2010 Apr;9(4):425-37. (PMID: 20298966)
      Annu Rev Immunol. 2005;23:225-74. (PMID: 15771571)
      Cell Immunol. 2009;254(2):149-54. (PMID: 18835598)
      Sci Transl Med. 2015 Sep 23;7(306):306ra151. (PMID: 26400912)
      mBio. 2016 Jul 05;7(4):. (PMID: 27381292)
      PLoS Pathog. 2008 Feb 8;4(2):e30. (PMID: 18266471)
      J Pediatr. 2005 Mar;146(3):423-5. (PMID: 15756234)
      J Virol. 2010 Apr;84(7):3270-9. (PMID: 20053749)
      Neurology. 2011 Sep 13;77(11):1061-7. (PMID: 21832229)
      J Immunol Methods. 2004 Nov;294(1-2):15-22. (PMID: 15604012)
      J Virol. 2001 Apr;75(7):3483-7. (PMID: 11238876)
      Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10160-5. (PMID: 20439706)
      J Neurovirol. 2013 Aug;19(4):351-8. (PMID: 23733308)
      Cancer Immunol Res. 2019 Jan;7(1):100-112. (PMID: 30396908)
      J Infect Dis. 2009 Mar 15;199(6):881-8. (PMID: 19434914)
      J Immunol. 2012 May 15;188(10):5054-62. (PMID: 22504653)
      J Clin Microbiol. 1997 May;35(5):1255-7. (PMID: 9114418)
      Cell Host Microbe. 2011 Feb 17;9(2):93-102. (PMID: 21320692)
      Cancer Immunol Res. 2015 Jun;3(6):575-82. (PMID: 26041808)
      Neurology. 2009 Apr 28;72(17):1458-64. (PMID: 19129505)
      Virology. 2010 Oct 10;406(1):12-20. (PMID: 20667578)
      Immunother Adv. 2021 Aug 13;1(1):ltab018. (PMID: 34604863)
      Virology. 1989 Jun;170(2):353-61. (PMID: 2543122)
      Neurology. 1999 Feb;52(3):623-5. (PMID: 10025799)
    • Grant Information:
      R01 NS116278 United States NS NINDS NIH HHS; R01 NS116278 United States NH NIH HHS
    • Contributed Indexing:
      Keywords: JC polyomavirus; NK cell antiviral immunity; NKG2D; ULBP
    • Accession Number:
      0 (GPI-Linked Proteins)
      0 (Intercellular Signaling Peptides and Proteins)
      0 (ULBP2 protein, human)
      0 (NK Cell Lectin-Like Receptor Subfamily K)
      82115-62-6 (Interferon-gamma)
      0 (KLRK1 protein, human)
    • Publication Date:
      Date Created: 20230929 Date Completed: 20240613 Latest Revision: 20240930
    • Publication Date:
      20240930
    • Accession Number:
      PMC11175686
    • Accession Number:
      10.1093/infdis/jiad424
    • Accession Number:
      37774496